AffyImmune Therapeutics is pioneering advancements in CAR T cell therapy, specifically targeting solid tumors through its innovative focus on ICAM-1 (Intercellular Adhesion Molecule 1). This molecule is overexpressed on the surface of certain cancer cells and serves as a critical binding site for LFA-1 (Lymphocyte Function-Associated Antigen 1) on T cells, enabling the immune system to effectively recognize and eliminate malignant cells. The company’s lead candidate, AIC100, is designed to enhance the immune response against anaplastic and advanced differentiated thyroid cancers, conditions that currently have poor prognoses. AffyImmune has received multiple FDA designations, including Orphan Drug and Regenerative Medicine Advanced Therapy, underscoring the potential impact of its therapies.

A key feature of AffyImmune's approach is the affinity tuning of CAR T cells, which optimizes their ability to selectively target and destroy cancerous cells while minimizing damage to healthy tissues. Additionally, the company has developed noninvasive monitoring technologies that allow for real-time tracking of CAR T cells in patients, reducing the burden of invasive procedures and improving overall patient care. This innovative strategy addresses significant challenges in cancer treatment, such as toxicity, antigen loss, and T cell exhaustion, thereby enhancing the efficacy and safety of CAR T therapies in clinical settings.

United States

Founded in 2016, AffyImmune is a clinical-stage biotechnology company that optimizes CAR T cells for the treatment of solid tumors using our Tune & Track platform. AIC100, our first product, spares healthy cells through our unique affinity-tuning, enhancing its safety and efficacy.

The initial indication for AIC100 is refractory thyroid cancer, which has a very poor prognosis and very few effective therapies. The antigen targeted by AIC100 is also overexpressed in a variety of additional cancers, including stomach, triple negative breast cancer and a number of others.

AffyImmune Therapeutics

Company Details